LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)

Phase 4 Completed 200 enrolled PETHEMA Foundation

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Prospective, multicenter, uncontrolled cohort study to analyze the efficacy of a risk adapted treatment strategy, including gemtuzumab ozogamicin (GO) during consolidation, for patients with acute myeloid leukemia (AML).

Timeline

Start: 2007-10
Primary completion: 2012-12
Completion: 2013-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gemtuzumab	Monoclonal antibody	3 mg/m2	—

LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)

Summary

Timeline

Drugs

Indications